Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma-Reference-Cited by-同舟云学术

Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma

Published:2015-04-17 Issue:6 Volume:31 Page:1105-1115
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Arikian Steven R.¹,Milentijevic Dejan²,Binder Gary³,Gibson Craig J.³,Hu X. Henry³,Nagarwala Yasir³,Hussein Mohamad³,Corvino Frank A.¹,Surinach Andy¹,Usmani Saad Z.⁴

Affiliation:

1. aGenesis Research, Hoboken, NJ, USA

2. bSpringfield, NJ, USA

3. cCelgene Corporation, Summit, NJ, USA

4. dLevine Cancer Institute/Carolinas Healthcare System, Charlotte, NC, USA

Publisher

Informa Healthcare

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1185/03007995.2015.1031732

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quality of end‐of‐life care in multiple myeloma: A 13‐year analysis of a population‐based cohort in Ontario, Canada;British Journal of Haematology;2022-08-10

2. Healthcare Resource Utilization and Cost of Patients with Multiple Myeloma in Germany: A Retrospective Claims Data Analysis;PharmacoEconomics - Open;2022-06-24

3. Association of High-Deductible Health Plan Enrollment With Spending on and Use of Lenalidomide Therapy Among Commercially Insured Patients With Multiple Myeloma;JAMA Network Open;2022-06-07

4. The relationship between cost and the recommendation, refusal, and discontinuation of treatment for chronic myeloid leukemia and multiple myeloma in Japan: a cross-sectional exploratory survey;Journal of Medical Economics;2022-05-02

5. Real-world analysis of patient characteristics, treatment outcomes, and healthcare resource utilization across Europe in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation who received lenalidomide- or bortezomib-based regimens;Leukemia & Lymphoma;2021-06-14